Annexon Biosciences

OverviewSuggest Edit

Annexon Biosciences' mission is to develops disease-modifying therapeutics for patients suffering from neurological disorders such as Huntington’s disease and Alzheimer’s disease by targeting complement-mediated neurodegeneration (CMND).

TypePrivate
Founded2011
HQSouth San Francisco, CA, US
Websiteannexonbio.com

Latest Updates

Employees (est.) (Apr 2021)48
Job Openings10
Cybersecurity ratingAMore

Key People/Management at Annexon Biosciences

Douglas Love

Douglas Love

President & CEO, Director
Thomas G. Wiggans

Thomas G. Wiggans

Board Chair, Former Founder, Chairman & CEO
Muneer Satter

Muneer Satter

Director
Emmett Cunningham

Emmett Cunningham

Board Member
Carol Gallagher

Carol Gallagher

Director
Ricky Sun

Ricky Sun

Director
Show more

Annexon Biosciences Office Locations

Annexon Biosciences has an office in South San Francisco
South San Francisco, CA, US (HQ)
180 Kimball Way
Show all (1)

Annexon Biosciences Financials and Metrics

Summary Metrics

Founding Date

2011

Annexon Biosciences total Funding

$179 m

Annexon Biosciences latest funding size

$100 m

Time since last funding

10 months ago

Annexon Biosciences investors

Annexon Biosciences's latest funding round in July 2020 was reported to be $100 m. In total, Annexon Biosciences has raised $179 m
Show all financial metrics

Annexon Biosciences Cybersecurity Score

Cybersecurity ratingPremium dataset

A

96/100

SecurityScorecard logo

Annexon Biosciences Online and Social Media Presence

Embed Graph

Annexon Biosciences News and Updates

Annexon Biosciences Reports Fourth Quarter and Full-Year 2020 Financial Results with Recent Business Highlights

SOUTH SAN FRANCISCO, Calif., March 25, 2021 (GLOBE NEWSWIRE) -- Today Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain and eye, announced fourth…

Annexon Biosciences Reports Second Quarter 2020 Financial Results and Recent Highlights

– Completed $263M IPO in July, and private financing in late June –

Annexon Biosciences Blogs

Annexon Announces Initiation of Phase 2/3 Trial of ANX005 in Patients with Guillain-Barré Syndrome

Annexon Announces Initiation of Phase 2/3 Trial of ANX005 in Patients with Guillain-Barré Syndrome Content Import Mon, 12/21/2020 - 07:00 Annexon Announces Initiation of Phase 2/3 Trial of ANX005 in Patients with Guillain-Barré Syndrome December 21, 2020 at 7:00 AM EST …

Annexon Biosciences Reports Third Quarter 2020 Financial Results and Recent Business Highlights

Annexon Biosciences Reports Third Quarter 2020 Financial Results and Recent Business Highlights Content Import Mon, 11/16/2020 - 16:01 Annexon Biosciences Reports Third Quarter 2020 Financial Results and Recent Business Highlights November 16, 2020 at 4:01 PM EST …

Annexon Expands Classical Complement Platform into Neurodegenerative Diseases of the Brain with Initiation of Huntington’s Disease Clinical Program

– First patient dosed in Phase 2 study of ANX005 C1q targeted mAb – SOUTH SAN FRANCISCO, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical

Annexon Biosciences Frequently Asked Questions

  • When was Annexon Biosciences founded?

    Annexon Biosciences was founded in 2011.

  • Who are Annexon Biosciences key executives?

    Annexon Biosciences's key executives are Douglas Love, Thomas G. Wiggans and Muneer Satter.

  • How many employees does Annexon Biosciences have?

    Annexon Biosciences has 48 employees.

  • Who are Annexon Biosciences competitors?

    Competitors of Annexon Biosciences include Lophius Biosciences, Mesoblast and TopiVert.

  • Where is Annexon Biosciences headquarters?

    Annexon Biosciences headquarters is located at 180 Kimball Way, South San Francisco.

  • Where are Annexon Biosciences offices?

    Annexon Biosciences has an office in South San Francisco.

  • How many offices does Annexon Biosciences have?

    Annexon Biosciences has 1 office.